AustraLian Ovarian Cancer Assortment Trial to perform comprehensive genetic screens on women diagnosed with ovarian cancer.

Not Applicable

Recruiting

• Conditions: Ovarian Cancer; Cancer - Ovarian and primary peritoneal

• Registration Number: ACTRN12615000576527
• Lead Sponsor: The University of Melbourne

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2015-06-03
• Last Update Posted: 13 January 2020

Recruitment & Eligibility

• Status: Recruiting
• Sex: Female
• Target Recruitment: 60

Inclusion Criteria

Women presenting at Royal Women's Hospital or the Peter MacCallum Cancer Centre with recurrent epithelial ovarian cancer (including peritoneal and fallopian tube cancers), regardless of histological subtype

Exclusion Criteria

Exclusion from collection of fresh biopsy tissue if not deemed safe. Archival FFPE (paraffinised tumour sample) from previous surgery will be used in this case.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Determination of the mutations involved in participants' tumours, compared with germline DNA extracted from blood using a customised next generation sequencing panel screening 30 genes associated with ovarian cancer for primary patient management[six to eight weeks after sample receipt]

Secondary Outcome Measures

Name	Time	Method
Clinical followup information and the genetic data from participants will be studied for patterns of mutations and drug responses by performing data linkage to patient medical records.[18 - 36 months after testing (retrospective)];Eventually, it is hoped the genetic data and followup data will facilitate the biological assortment and selection of suitable patients for clinical trials of approved and investigational-targeted therapies[36+ months after testing (retrospective)]